Table of contents for Vascular-targeted therapies in oncology / editor, Dietmar W. Siemann.

Bibliographic record and links to related information available from the Library of Congress catalog.

Note: Contents data are machine generated based on pre-publication provided by the publisher. Contents may have variations from the printed book or be incomplete or contain other coding.


Counter
Contents
Preface
List of Contributors
1 ? Introduction 
Dietmar W. Siemann
1.1 Introduction
1.2 Tumor vasculature
1.3 Impact of tumor microenvironments on cancer management
1.4 Vascular-targeting therapies
1.5 Combinations with conventional anticancer therapies
1.6 Combinations of antiangiogenic and vascular-disrupting agents
1.7 Conclusions
Acknowledgements
References
2 ? Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors 
Peter Vaupel
2.1 Introduction
2.2 Basic principles of blood vessel formation in tumors
2.3 Tumor lymphangiogenesis
2.4 Tumor vascularity and blood flow
2.5 Volume and composition of the tumor interstitial space
2.6 Fluid pressure and convective currents in the interstitial space of tumors
2.7 Evidence, characterization and pathogenesis of tumor hypoxia
2.8 Tumor pH
2.9 The ?crucial Ps? characterizing the hostile metabolic microenvironment of solid tumors
Acknowledgement
References
3 ? The Role of Microvasculature in Metastasis Formation 
Oliver St¿ltzing
Lee M. Ellis
3.1 Introduction
3.2 Regulators of angiogenesis in solid tumors
3.3 Angiogenesis and metastasis formation
3.4 Summary
References
4 ? Development of Vascular Targeting Strategies 
David Chaplin
Sally A. Hill
4.1 Introduction
4.2 Early history
4.3 Formulation of the VDA concept
4.4 Effects of vascular occlusion on tumor cell survival
4.5 Rational development of VDA therapeutics
4.6 Development of small-molecule VDAs
4.7 Combretastatin A4 phosphate
4.8 The viable rim
4.9 Conclusions
References
5 ? Morphologic Manifestations of Vascular-Disrupting Agents in Preclinical Models 
Mumtaz V. Rojiani
Amyn Rojiani
5.1 Introduction
5.2 Animal models
5.3 Morphologic and morphometric analysis
5.4 Effects of treatment
Acknowledgements
References
6 ? The Discovery and Development of Vascular-Disrupting Agents 
Kevin G. Pinney
6.1 Introductory comments
6.2 Colchicine-binding site on tubulin
6.3 Brief overview of tubulin biology
6.4 Small-molecule inhibitors of tubulin assembly
6.5 Design paradigm for small-molecule vascular-targeting agents
6.6 Concluding remarks
Acknowledgements
References
7 ? Combined Modality Approaches Using Vascular-Disrupting Agents 
Wenyin Shi
Michael R. Horsman
Dietmar W. Siemann, PhD 
7.1 Tumor vasculature
7.2 Vascular-disrupting strategies
7.3 VDAs and chemotherapy
7.4 VDAs and radiation therapy
7.5 VDAs and antiangiogenic agents
7.6 Summary
Acknowledgements
 References
8 ? Vascular-Targeting Therapies and Hyperthermia 
Michael R. Horsman
Rumi Murata
8.1 Introduction
8.2 Enhancing hyperthermia
8.3 Enhancing thermoradiotherapy
8.4 Conclusions and clinical relevance
Acknowledgements
References
9 ? Flavones and Xanthenones as Vascular-Disrupting Agents 
Bronwyn Siim
Bruce Baguley
9.1 Development of FAA and DMXAA
9.2 Antivascular activity of FAA and DMXAA
9.3 Cytokine induction by FAA and DMXAA
9.4 Molecular target
9.5 Preclinical studies: DMXAA as a single agent
9.6 Preclinical studies: combination treatments
9.7 Species differences
9.8 Clinical studies
References
10 ? Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer
Adam W. Beck
Rolf Brekken
Philip E. Thorpe, PhD 
10.1 Vascular targeting
10.2 Pancreatic cancer: the clinical need
10.3 Phosphatidylserine
10.4 Proof of concept studies
10.5 Combined treatment with 3G4 and gemcitabine in a pancreatic cancer model
10.6 Mechanism of action
10.7 Conclusion
References
11 ? Cadherin Antagonists as Vascular-Targeting Agents 
Orest Blaschuk
Tracey M. Rowlands
11.1 Pericytes as regulators of blood vessel stability
11.2 Cadherins
11.3 Cadherins and the vasculature
11.4 Tumor vasculature
11.5 Manipulation of the tumor vasculature with cadherin antagonists
11.6 Summary and future directions
Acknowledgements
References
12 ? Alphastatin: a Pluripotent Inhibitor of Activated Endothelial Cells 
Carolyn A. Staton
Claire Lewis 
12.1 Introduction
12.2 Discovery of alphastatin
12.3 Development of alphastatin
12.4 Conclusions
References
13 ? Cationic Lipid Complexes to Target Tumor Endothelium 
Uwe Michaelis
Michael Teifel
13.1 Introduction
13.2 Tumor vascular targeting by cationic liposomes
13.3 Potential targets for cationic lipid complexes on tumor endothelial cells
13.4 Cationic liposomes as drug carriers
13.5 Side-effects of intravenously administered cationic lipid complexes
13.6 Preclinical data
13.7 Clinical data
13.8 Conclusion
 References
14 ? Development of Vascular-Targeted Cancer Gene Therapy 
Graeme J. Dougherty
Peter D. Davis
Shona T. Dougherty
14.1 Introduction
14.2 Advantages of tumor vasculature as a target in cancer gene therapy
14.3 Genes of value in vascular-targeted cancer gene therapy
14.4 Targeting gene therapy to tumor vasculature
14.5 Concluding remarks
Acknowledgement
References
15 ? Vascular-Disrupting Strategies Combined with Bacterial Spores Targeting Hypoxic Regions of Solid Tumors 
G-One Ahn
J. Martin Brown
15.1 Hypoxia and necrosis as a selective target for cancer therapy
15.2 Use of Clostridia as hypoxia/necrotic selective cancer therapy
15.3 Advantage of CDEPT over ADEPT and GDEPT
15.4 Combination of CDEPT with vascular-disrupting agents
15.5 Clinical significance
References
16 ? Imaging the Effects of Vascular-Targeting Agents 
Susan M. Galbraith
16.1 Introduction
16.2 Methods for imaging tissue blood flow rate
16.3 Central volume theorem
16.4 Kety model
16.5 Fraction of cardiac output or ?first-pass? methods
16.6 Color Doppler ultrasonography
16.7 Imaging hypoxia
16.8 Imaging glucose metabolism
16.9 Preclinical experience of imaging vascular-disrupting agents
16.10 Clinical experience of imaging vascular-disrupting agents
16.11 Conclusions
References
17 ? Clinical Progress in Tumor Vascular-Disrupting Therapies 
Andy Gaya
Gordon Rustin
17.1 Introduction
17.2 Potential clinical advantages of vascular-disrupting agents
17.3 Biological (ligand-directed) VDAs
17.4 Small-molecule VDAs
17.5 Potential surrogate markers of CA4P activity
17.6 Combination therapy with VDAs
17.7 VDAs in non-malignant diseases
17.8 Conclusions
References
18 ? Use of Vascular-Disrupting Agents in Non-Oncology Indications 
Joseph C. Randall
Scott Young
18.1 Background
18.2 Age-related macular degeneration (AMD)
18.3 Myopic macular degeneration
18.4 Retinopathy of prematurity
18.5 Proliferative diabetic retinopathy
18.6 Pediatric hemangiomas
18.7 Arthritis
18.8 Psoriasis
18.9 Conclusions
References

Library of Congress Subject Headings for this publication:

Cancer -- Chemotherapy.
Neovascularization inhibitors.
Blood-vessels -- Effects of drugs on.
Neovascularization.
Neoplasms -- drug therapy.
Angiogenesis Inhibitors -- therapeutic use.
Blood Vessels -- drug effects.
Drug Delivery Systems.
Endothelial Cells -- drug effects.
Gene Therapy -- methods.
Neovascularization, Pathologic.